![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 12
Zeitschriftenartikel
Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J.
(2022):
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567
Dent, S.; Cortes, J.; Im, Y.-H.; Dieras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P. und Jacot, W.
(2021):
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
In: Annals of Oncology, Bd. 32, Nr. 2: S. 197-207
Gennari, A.; Andre, F.; Barrios, C. H.; Cortes, J.; de Azambuja, E.; DeMichele, A.; Dent, R.; Fenlon, D.; Gligorov, J.; Hurvitz, S. A.; Im, S. -a.; Krug, D.; Kunz, W. G.; Loi, S.; Penault-Llorca, F.; Ricke, J.; Robson, M.; Rugo, H. S.; Saura, C.; Schmid, P.; Singer, C. F.; Spanic, T.; Tolaney, S. M.; Turner, N. C.; Curigliano, G.; Loibl, S.; Paluch-Shimon, S. und Harbeck, N.
(2021):
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
In: Annals of Oncology, Bd. 32, Nr. 12: S. 1475-1495
Harbeck, N.; Rastogi, P.; Martin, M.; Tolaney, S. M.; Shao, Z. M.; Fasching, P. A.; Huang, C. S.; Jaliffe, G. G.; Tryakin, A.; Goetz, M. P.; Rugo, H. S.; Senkus, E.; Testa, L.; Andersson, M.; Tamura, K.; Del Mastro, L.; Steger, G. G.; Kreipe, H.; Hegg, R.; Sohn, J.; Guarneri, V.; Cortes, J.; Hamilton, E.; Andre, V.; Wei, R.; Barriga, S.; Sherwood, S.; Forrester, T.; Munoz, M.; Shahir, A.; San Antonio, B.; Nabinger, S. C.; Toi, M.; Johnston, S. R. D. und O'Shaughnessy, J.
(2021):
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
In: Annals of Oncology, Bd. 32, Nr. 12: S. 1571-1581
Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M. S.; Andre, F.; Barrios, C. H.; Bergh, J.; Bhattacharyya, G. S.; Biganzoli, L.; Boyle, F.; Cardoso, M-J; Carey, L. A.; Cortes, J.; El Saghir, N. S.; Elzayat, M.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Gligorov, J.; Haidinger, R.; Harbeck, N.; Hu, X.; Kaufman, B.; Kaur, R.; Kiely, B. E.; Kim, S.-B.; Lin, N. U.; Mertz, S. A.; Neciosup, S.; Offersen, B. V.; Ohno, S.; Pagani, O.; Prat, A.; Penault-Llorca, F.; Rugo, H. S.; Sledge, G. W.; Thomssen, C.; Vorobiof, D. A.; Wiseman, T.; Xu, B.; Norton, L.; Costa, A. und Winer, E. P.
(2020):
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
In: Annals of Oncology, Bd. 31, Nr. 12: S. 1623-1649
Yardley, D. A.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; de la Cruz-Merino, L.; Wilks, S.; O'Shaughnessy, J.; Gluck, S.; Li, H.; Miller, J.; Barton, D. und Harbeck, N.
(2018):
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
In: Annals of Oncology, Bd. 29, Nr. 8: S. 1763-1770
Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; Andre, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C. H.; Bergh, J.; Biganzoli, L.; Börs-Doers, C. B.; Cardoso, M. J.; Carey, L. A.; Cortes, J.; Curigliano, G.; Dieras, V.; El Saghir, N. S.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Johnston, S. R. D.; Kaufmann, B.; Koppikar, S.; Krop, I. E.; Mayer, M.; Nakigudde, G.; Offersen, B. V.; Ohno, S.; Pagani, O.; Paluch-Shimon, S.; Penault-Llorca, F.; Prat, A.; Rugo, H. S.; Sledge, G. W.; Spence, D.; Thomssen, C.; Vorobiof, D. A.; Xu, B.; Norton, L. und Winer, E. P.
(2018):
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
In: Annals of Oncology, Bd. 29, Nr. 8: S. 1634-1657
Gennari, A.; Brain, E.; Nanni, O.; Couselo, E. Munoz; Harbeck, N.; Geiss, R.; Rocca, A.; Cortes, J.; Degenhardt, T.; Piccardo, A.; Alberini, J-L.; Matteucci, F.; Decensi, A.; Corradengo, D. S.; Andreis, D.; Marra, D.; Gebhart, G.; Brambati, C.; Amadori, D. und Bruzzi, P.
(2017):
Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program.
In: Annals of Oncology, Bd. 28
Brain, E.; Corradengo, D.; Oriana, N.; Piccardo, A.; Matteucci, F.; Cortes, J.; Harbeck, N.; Würstlein, R.; Piris, A.; Alberini, J.-L.; Merlo, D. F.; Degenhardt, T.; Turbiez, I.; Madar, O.; Monti, M.; Cesaro, A.; Rivitti, E.; Rollandi, G. A.; Iacozzi, M.; Campazzi, E.; Campora, S.; Camporese, D. und Gennari, A.
(2017):
Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011.
In: Cancer Research, Bd. 77
Yardley, D.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; Cruz Merino, L. de la; Wilks, S.; O'Shaugnessy, J.; Glück, S.; Li, H.; Beck, R.; Barton, D. und Harbeck, N.
(2017):
nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial.
In: Cancer Research, Bd. 77
Hadji, P.; Coleman, R. E.; Wilson, C.; Powles, T. J.; Clezardin, P.; Aapro, M.; Costa, L.; Body, J.-J.; Markopoulos, C.; Santini, D.; Diel, I.; Di Leo, A.; Cameron, D.; Dodwell, D.; Smith, I.; Gnant, M.; Gray, R.; Harbeck, N.; Thurlimann, B.; Untch, M.; Cortes, J.; Martin, M.; Albert, U.-S.; Conte, P.-F.; Ejlertsen, B.; Bergh, J.; Kaufmann, M. und Holen, I.
(2016):
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
In: Annals of Oncology, Bd. 27, Nr. 3: S. 379-390
Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J. und Harbeck, N.
(2016):
Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer.
In: Oncology Research and Treatment, Bd. 39: S. 182-183